The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of ponatinib to inhibit kinase mutations associated with drug-resistant gastrointestinal stromal tumors (GIST).
Michael C. Heinrich
Consultant or Advisory Role - ARIAD
Stock Ownership - MolecularMD
Research Funding - ARIAD
Jonathan A. Fletcher
Consultant or Advisory Role - ARIAD; Novartis; Pfizer
Honoraria - Novartis
Rana Anjum
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Cesar Serrano-Garcia
No relevant relationships to disclose
Sadanand Vodala
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Sebastian Bauer
Honoraria - Bayer; Novartis; Pfizer
Ajia Town
No relevant relationships to disclose
Meijun Zhu
No relevant relationships to disclose
Yaoyu Ning
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Grant Eilers
No relevant relationships to disclose
Diana Griffith
No relevant relationships to disclose
Janice Patterson
No relevant relationships to disclose
Arin McKinley
No relevant relationships to disclose
Frank Y Wang
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Andrew P Garner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD